Rodman & Renshaw reiterates its Outperform rating on Onyx Pharmaceuticals ONXX and raises its rice target from $57 to $73.
Rodman & Renshaw notes, "The carfilzomib (Kyprolis) ODAC panel voted overwhelmingly in favor of recommending the drug for approval, removing, in our view, most, if not all, regulatory risk with the drug's NDA ahead of its July 27th PDUFA date."
ONXX closed at $44.58 on Wednesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in